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Background: The role of cerebrospinal fluid (CSF) biomarkers, and neuroimaging in 
the diagnostic process of Alzheimer’s disease (AD) is not clear, in particular in the older 
patients.
Objective: The aim of this study was to compare the clinical diagnosis of AD with CSF 
biomarkers and with cerebrovascular damage at neuroimaging in a cohort of geriatric 
patients.
Methods: Retrospective analysis of medical records of ≥65-year-old patients with 
cognitive impairment referred to an Italian geriatric outpatient clinic, for whom the CSF 
concentration of amyloid-β (Aβ), total Tau (Tau), and phosphorylated Tau (p-Tau) was 
available. Clinical diagnosis (no dementia, possible and probable AD) was based on the 
following two sets of criteria: (1) the Diagnostic Statistical Manual of Mental Disorders 
(DSM-IV) plus the National Institute of Neurological and Communicative Disorders and 
Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) 
and (2) the National Institute on Aging-Alzheimer’s Association (NIA-AA). The Fazekas 
visual scale was applied when a magnetic resonance imaging scan was available.
results: We included 94 patients, mean age 77.7  years, mean Mini Mental State 
Examination score 23.9. The concordance (kappa coefficient) between the two sets 
of clinical criteria was 70%. The mean CSF concentration (pg/ml) (±SD) of biomarkers 
was as follows: Aβ 687 (±318), Tau 492 (±515), and p-Tau 63 (±56). There was a trend 
for lower Aβ and higher Tau levels from the no dementia to the probable AD group. The 
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percentage of abnormal liquor according to the local cutoffs was still 15 and 21% in 
patients without AD based on the DSM-IV plus NINCDS-ADRDA or the NIA-AA criteria, 
respectively. The exclusion of patient in whom normotensive hydrocephalus was sus-
pected did not change these findings. A total of 80% of patients had the neuroimaging 
report describing chronic cerebrovascular damage, while the Fazekas scale was positive 
in 45% of patients overall, in 1/2 of no dementia or possible AD patients, and in about 
1/3 of probable AD patients, with no difference across ages.
conclusion: We confirmed the expected discrepancy between different approaches to 
the diagnosis of AD in a geriatric cohort of patients with cognitive impairment. Further 
research is needed to understand how to interpret this discrepancy and provide clinicians 
with practical guidelines.
Keywords: alzheimer, aging, clinical criteria, biomarkers, neuropsychological tests, cerebrovascular disease
inTrODUcTiOn
For decades, Alzheimer’s disease (AD) has been diagnosed only 
based on clinical criteria (1). With the increasing knowledge of 
the pathogenic processes underlying this and other dementias, 
several biomarkers have been proposed to support the diag-
nosis, also at early stages (2–4). Biomarkers are defined as any 
objective measurement of an in vivo pathological process (5). 
Cerebrospinal fluid (CSF) proteins [amyloid-β (Aβ) protein, 
total Tau (Tau), and phosphorylated Tau (p-Tau)] and func-
tional and anatomical neuroimaging findings represent the 
most studied biomarkers of AD.
The role of these biomarkers in the diagnosis of AD in clini-
cal practice has not been completely clarified yet, as both the 
American (1) and International Working Group Guidelines (6) 
underline. Understanding their role in the diagnostic work-
flow might be particularly challenging in an older population 
(>85  years) presenting with cognitive impairment. There is 
evidence suggesting that, as age increases, the prevalence of 
pathological patterns that have been associated with the disease, 
increases also in subjects without cognitive impairment (7, 8). 
Also, the association between the presence of neuritic plaques 
in autoptic specimens and dementia is less strong in older peo-
ple (9, 10). Changes in neuroimaging may be less salient in the 
older ages, in which atrophy often coexists with cerebrovascular 
damage. Furthermore, chronic cerebrovascular disease is such 
a frequent neuroimaging finding that its contribution to the 
cognitive deficit remains difficult to define, especially when 
not properly quantified (11). Finally, in the oldest patients, the 
burden of comorbidities often makes the scenario more com-
plex (6). All these reasons increase the chance of conflicting 
findings between biomarkers and clinical symptoms. The whole 
picture is further complicated by the fact that the existing sets 
of diagnostic criteria for AD proposed by different scientific 
societies assign a different place to some clinical symptoms and 
signs. In fact, the diagnostic criteria have changed over time, 
integrating the new knowledge upon the disease mechanisms 
and biomarkers and reflecting different disease definitions 
(1, 6, 12). However, the newer criteria have not replaced the 
older ones, which are still being used in clinical research, and 
in particular in studies evaluating therapies for AD (13). The 
dimension of the problem can be substantial and represents 
a barrier to a straightforward diagnostic process in routine 
practice, especially in those clinical settings providing care to 
less selected older patients such as geriatrics.
With such a background, the objective of our study was to 
represent the level of discrepancy between different diagnostic 
approaches, describing a population of older patients with 
cognitive impairment referred to an Italian geriatric outpatient 
clinic. In particular, we compared the diagnosis based on clini-
cal criteria with the CSF biomarkers and with cerebrovascular 
damage finding at neuroimaging.
MaTerials anD MeThODs
study Design and Population
This is a retrospective cross-sectional study of medical records 
of 65-year-old or older patients, referred to the Alzheimer 
Evaluation Unit (UVA) of the Division of Geriatrics of the 
IRCCS Ca’ Granda Ospedale Maggiore Policlinico in Milan 
between June 2009 and October 2014. Ethical approval was 
not required for this study in accordance with the institutional 
guidelines.
We included in the study all those patients with a cognitive 
impairment who underwent at physician’s discretion a lumbar 
puncture during the diagnostic workup and for whom the 
concentration of Aβ, Tau, and p-Tau in the CSF was available. 
There was no exclusion criterion. In particular, as per our prac-
tice, patients undergo a lumbar puncture with liquor collection 
and examination: (i) in the context of differential diagnosis of 
dementia, when the treating physician deems it as necessary to 
help confirm or rule out a clinical suspicion of AD, and (ii) in the 
context of diagnosis and therapy (i.e., ex juvantibus) of normo-
tensive hydrocephalus.
All patients undergo the lumbar puncture only if a specific 
written informed consent was provided by the patient or by 
her/his next of kin.
Retrospectively, but in a blind fashion with respect to the 
actual diagnosis made by the treating physician, we characterized 
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the patients according to different diagnostic approaches. 
We first classified the patients using two different sets of clinical 
diagnostic criteria for AD (not taking into account the labora-
tory findings) and then compared the clinical diagnoses with 
the results of CSF biomarkers. Second, we described the preva-
lence of signs of vascular damage at neuroimaging according to 
different approaches, i.e., standard descriptive reports versus 
visual quantitative scales, and its correlation with the clinical 
and the liquor-based classifications. Within this framework, we 
also evaluated the contribution of neuropsychological (NPS) 
tests in making the diagnosis of AD. In fact, it is known that 
many patients with cognitive impairment have poor awareness 
or understanding of their cognitive impairment (14). Thus, an 
objective cognitive assessment lies at the core of an appropriate 
diagnostic workup for cognitive decline. Moreover, NPS tests 
can help define early or prodromal states like a mild cognitive 
impairment (MCI), in which biomarkers might be already 
positive (6, 15, 16). Finally, all the patients for whom a brain 
magnetic resonance imaging scan was available were included 
in the sub-study on neuroimaging.
To have an objective comparison across different diagnostic 
tools, we included all patients with a CSF record, regardless 
of the final diagnosis made by the treating physician. Patients 
with a clinical suspicion of normotensive hydrocephalus were 
included in the main analyses as expected negative cases 
(i.e., cases in which CSF biomarkers were expected to be nega-
tive). They were then excluded as a sensitivity analysis.
Data collection
Patient medical records temporarily close but preceding the 
time of the lumbar puncture were evaluated for the purpose of 
our study. The study investigators were guarantor for protecting 
the confidential data from any inappropriate use beyond the 
purpose of this study.
Clinical Diagnostic Criteria and NPS Assessment
Two investigators (GD and AG) screened the patient charts 
independently and retrospectively reanalyzed medical records 
of patients included in the study, being blinded to the diagnosis 
that was made by the treating geriatrician. Clinical diagnosis of 
dementia and of AD was based on the criteria of the Diagnostic 
Statistical Manual of Mental Disorders (DSM-IV) (17) and of 
the National Institute of Neurological and Communicative 
Disorders and Stroke and the Alzheimer’s Disease and Related 
Disorders Association (NINCDS-ADRDA) 1984 (18), respec-
tively (Appendix in Supplementary Material). Patients were also 
classified according to the criteria for dementia and AD of the 
National Institute on Aging-Alzheimer’s Association (NIA-AA) 
2011 (1) (Appendix in Supplementary Material). Based on each 
of the two sets of clinical criteria, patients were classified into 
no dementia, possible AD, and probable AD. The results of the 
following clinical investigations were taken into account for the 
classification of each patient upon those criteria, when available: 
the multidimensional geriatric assessment, blood tests, NPS 
tests, and neuroimaging. In particular, we relied on the results 
of the NPS assessment, when available, in case of inconsistency 
between the NPS report and the record of the geriatric visit for 
what concerned the presence of memory deficits and the level 
of impact on function. In order to preserve the comparative 
analyses of our sub-study, when we applied the clinical diagnos-
tic criteria, we used the neuroimaging reports only to rule out 
the presence of a clear alternative diagnosis (i.e., normotensive 
hydrocephalus, multi-infarct disease, and tumor). The descrip-
tive finding of “leukoaraiosis” or “chronic cerebrovascular 
disease” was not considered sufficient for meeting the criterion 
of an alternative (i.e., vascular) etiology of dementia.
We looked for the NPS assessment that preceded or coin-
cided with the date of the lumbar puncture. In patients with 
multiple assessments, we used the outcome of the assessment 
that was temporarily closer to the date of the lumbar puncture. 
We used the outcome of NPS tests performed after the lumbur 
puncture only if temporarily very close (no more than 1 month 
later). The battery of NPS tests was administered by an expert 
neuropsychologist. Global cognitive functioning was assessed 
by means of the Mini Mental State Examination (MMSE) (19) 
and general intellectual functioning was investigated by using 
Raven’s colored progressive matrices (20). For temporal orienta-
tion, the first item of the MMSE was considered. Anterograde 
long-term memory was rated with the prose recall test (21) and 
the delayed recall of the Rey–Osterreith complex figure test 
(17). Verbal short-term memory was assessed by means of the 
forward digit span test (18). The digit cancelation test (21) was 
administered to examine visual attention. Executive prefrontal 
functions were evaluated using the backward digit span test (17), 
the trail-making test (22), and the phonological fluency test (23). 
Spatial skills were divided into spatial orientation, assessed by 
the second item of the MMSE, and spatial abilities, explored by 
means of the copy of geometrical figure test (20) and the copy 
of the Rey–Osterreith complex figure test (17). Language was 
examined using the picture-naming test (24). All tests, excepted 
for the orientation one, have been validated and standardized 
in a sample of healthy Italian subjects. Most of the normative 
data are referred to the study from Spinnler and Tognoni (21). 
According to the outcome of the NPS assessment, patients were 
classified into: normal cognition, MCI, or diffuse/severe cogni-
tive impairment. Patients classified as MCI were divided into the 
following four subtypes: only memory domain affected, single-
domain MCI with a deficit other than on memory domain, mul-
tiple domain MCI with memory domain affected, and multiple 
domain MCI with deficits other than on memory domain.
CSF Biomarkers
The lumbar puncture was performed according to procedural 
standards. The dosage of Aβ protein, Tau, and p-Tau in the 
liquor was performed on site. The cerebrospinal fluid sample 
was centrifuged at 4°C and stored at −30°C until analysis. 
Aβ42 protein, Tau and p-Tau 181 were determined by ELISA 
kits (Innogenetics). The local laboratory cutoff points for nor-
mal protein concentrations are as follows: Aβ42 >  600 pg/ml, 
Tau < 500 pg/ml, and p-Tau < 61 pg/ml.
Neuroimaging
Available brain MRI images were examined independently and 
retrospectively by three operators blinded to the patient clinical 
TaBle 1 | Baseline characteristics.
characteristics Distribution
Mean age (SD), years 77.7 (5.2)
Female, n (%) 58 (61.7)
Mean MMSE (SD) 23.9 (4.1)
Mean basic ADL score (SD) 4.7 (1.6)a
Mean instrumental ADL score (SD) 4.3 (2.5)a,b
History of hypertension, n (%) 58 (61.7)
History of diabetes mellitus, n (%) 18 (19.1)
History of dyslipidemia, n (%) 40 (42.5)
Smoker, n (%)
Yes 53 (53.4)
No 10 (10.6)
Ex 31 (33.0)
History of coronary artery disease, n (%) 9 (9.6)
History of stroke or TIA, n (%) 8 (8.5)
History of peripheral artery disease, n (%) 4 (4.2)
Carotid atherosclerosis, n (%) 43 (45.7)c
n, number; MMSE, Mini Mental State Examination; ADL, activity of daily living;  
TIA, transient ischemic attack.
aInformation missing for one patient.
bIn 35 patients (30 men), The maximum number of applicable items was less than 8.
cStenosis of at least 20% at the US scan.
TaBle 3 | Comparison of Diagnostic Statistical Manual of Mental Disorders 
(DSM-IV) plus National Institute of Neurological and Communicative Disorders 
and Stroke and the Alzheimer’s Disease and Related Disorders Association 
(NINCDS-ADRDA) and National Institute on Aging-Alzheimer’s Association (NIA-
AA) criteria for the diagnosis of Alzheimer’s disease (AD).
clinical diagnostic  
criteria
nia-aa criteria
no 
dementia, 
n (%)
Possible aD, 
n (%)
Probable 
aD, n (%)
Total,  
n (%)
DSM-iV plus  
nincDs-
aDrDa 
criteria
no dementia, 
n (%)
39 (71) 16 (29) 0 (0) 55 (58)
Possible aD, 
n (%)
0 (0) 11 (85) 2 (15) 13 (14)
Probable aD, 
n (%)
0 (0) 0 (0) 26 (100) 26 (28)
Total, n (%) 39 (41) 27 (29) 28 (30) 94 (100)
TaBle 2 | Availability of data on the different diagnostic approaches in the study 
cohort.
Diagnostic approach number of patients with data 
(% of the total cohort)
Clinical criteria 94 (100)
CSF biomarkers 94 (100)
NPS assessment 71 (75)
Neuroimaging—standard report 76 (81)
Neuroimaging—Fazekas scale 40 (42)
CSF, cerebral spinal Cerebrospinal fluid; NPS, neuropsychological.
4
Dolci et al. Challenges in Alzheimer’s Disease Diagnosis
Frontiers in Medicine | www.frontiersin.org November 2017 | Volume 4 | Article 203
history. The Fazekas visual scale (25) was applied on at least one 
long TR sequence, Flair or T2. Given the smallest number of miss-
ing data, for the purpose of the analysis, only axial plane images 
were considered. The Fazekas scores range from 0 (normal) to 
3 (extensive, diffuse, and confluent lesions of the subcortical 
white matter). For the purpose of our analyses, we dichotomized 
the Fazekas scores into negative (0 or 1) and positive (≥2). 
We chose this cutoff in order to be more specific in this popula-
tion at high prevalence of chronic cerebrovascular damage.
We decided not to include the assessment of atrophy accord-
ing to the qualitative versus quantitative approach in our com-
parative analyses, because only a very small subgroup of patients 
had suitable MRI images to apply atrophy quantitative scales. 
Functional neuroimaging (positron emission tomography) was 
available only for few patients.
statistical analysis
Descriptive statistics (mean, SD, median and range in case of 
numerical variables, and frequency in case of categorical varia-
bles) were used to present the classification of patients according 
to the clinical criteria (DSM-IV plus NINCDS-ADRDA versus 
NIA-AA), the CSF biomarkers, and the neuroimaging biomark-
ers of cerebrovascular disease. First, the two different clinical 
criteria were compared and the concordance was measured by 
Cohen’s kappa calculation (to take into account the effect of 
chance). Distributions of biomarkers were compared with the 
clinical diagnoses according to the NIA-AA criteria, using cross 
tabulations and Pearson χ2 or Kruskal–Wallis test, in the whole 
cohort and by age groups. As sensitivity analyses, the com-
parison was repeated (i) excluding patients that underwent the 
lumber puncture in the context of a suspicion of normotensive 
hydrocephalus and (ii) taking into account the NPS diagnosis. 
Inter-rater reproducibility for the MRI visual scales was also 
calculated as Kappa.
resUlTs
The clinical records of 94 patients were examined. Table  1 
shows the baseline characteristics of the study cohort. In most 
of the cases (68%), the lumbar puncture was performed in the 
context of a differential diagnosis for AD. In 11 of these 64 
patients, alternative dementia etiologies were considered: Lewi 
Body Dementia in four patients; Fronto-Temporal Dementia in 
six patients (in one of these patients normotensive hydrocepha-
lus etiology was also under consideration); and subclinical 
hypothyroidism in one patient. In 30 patients, normotensive 
hydrocephalus was the main diagnostic hypothesis and the 
main reason for the lumbar puncture.
Table 2 summaries the availability of data for the comparison 
of the different diagnostic tools.
classifications according to clinical 
Diagnostic criteria and csF Biomarkers
A total of 55 (58%), 13 (14%), and 26 (28%) patients were classi-
fied as being affected by no dementia, possible AD, and probable 
AD, respectively, according to the DSM-IV plus NINCDS-ADRDA 
criteria; 39 (41%), 27 (29%), and 28 (30%), respectively, according 
to the NIA-AA. As pre-specified, criterion on the presence of 
memory deficits was fulfilled using the objective outcome of the 
NPS assessment. In fact, 64% of those patients who had no objec-
tive memory deficit at the NPS tests had expressed a memory 
complaint during the clinical visit.
Table  3 compares patient classification according to the 
DSM-IV plus NINCDS-ADRDA with the NIA-AA clinical 
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criteria. Every patient who was classified as demented according 
to the DSM-IV criteria was also classified as demented accord-
ing to the NIA-AA criteria; whereas 29% classified as demented 
according to the NIA-AA criteria were not demented according 
to DSM-IV criteria. The crude concordance between the two 
sets of criteria for the diagnosis of dementia was 83%, with a 
kappa coefficient of 67%. The crude concordance for the specific 
diagnosis (no dementia, possible and probable AD) between the 
two criteria was 81% with a kappa of 70%.
The mean (SD) value of Aβ, Tau, and p-Tau in the study 
population was 687 pg/ml (318), 492 pg/ml (515), and 63 pg/ml 
(56), respectively. According to the local laboratory cutoffs, Aβ 
and Tau values were on average normal whereas mean p-Tau 
values were abnormal (high).
There was a statistically significant difference in the CSF 
concentration of Aβ and Tau but not of p-Tau, across the three 
diagnoses made according to both NINCDS-ADRDA and 
NIA-AA criteria (Figure  1). In particular, there was a trend 
for lower Aβ values and higher Tau levels going from the no 
dementia group to probable AD group, more evident in the case 
of the NINCDS-ADRDA diagnoses.
When the biomarkers levels were dichotomized based 
on local lab cutoffs into positive (i.e., abnormal) or negative  
(i.e., normal), the frequency of biomarkers positivity differed 
across the diagnoses in a statistically significant way only for 
Aβ, with both DSM-IV plus NINCDS-ADRDA and NIA-AA 
classification (4). Every biomarker tended to be more frequently 
positive in the case of patients with a diagnosis of probable AD 
compared to patients with a diagnosis of possible AD or no 
dementia (Table  4). Compared to patients with no dementia, 
patients with possible AD tended to present with positive 
biomarkers more frequently when DSM-IV plus NINCDS-
ADRDA criteria were used but less frequently when NIA-AA 
criteria were used (Table 4).
Then, the CSF biomarkers were considered as a whole and the 
patient classified as having positive liquor only when the level of 
all the three proteins was abnormal (i.e., reduced Aβ, elevated 
Tau, and p-Tau). In this case, only 18 patients (19%) had positive 
liquor. Patients with positive liquor were on average younger than 
those with negative liquor [mean age 74.7 (SD ±3.7) versus 77.2 
(SD ±2.7), p for Kruskal–Wallis test = 0.002].
Table 5 shows the distribution of the liquor biomarker accord-
ing to the different diagnoses and to different age groups. The 
trend for positive liquor was the same in the whole population 
and in the two age groups, with a higher prevalence of positive 
liquor in probable AD than in possible AD and no dementia, in 
both clinical classifications. The prevalence was again higher in 
those with no dementia than in those with possible dementia in 
the case of NIA-AA criteria. In any age group and in any clinical 
diagnosis group, a negative liquor was more prevalent than posi-
tive liquor (Table 5).
When we considered age cutoffs progressively lower than 
80, the percentage of patients with positive liquor became 
higher than the percentage of patients with negative liquor 
only among patients with a diagnosis of probable AD (any set 
of criteria) younger than 76  years (66% positive versus 33% 
negative).
Thirty of the 94 patients underwent a lumbar puncture in 
the context of a clinical suspicion of normotensive hydrocepha-
lus. When re-classified in a blinded fashion according to the 
two sets of clinical criteria, these patients were all classified as 
with no dementia according to the DSM-IV criteria. According 
to the NIA-AA criteria, 19 (63%) patients were not demented 
and 11 (27%) patients had a possible AD. Table  6 shows the 
comparison between the clinical (NIA-AA criteria) and the liq-
uor diagnoses when patients with normotensive hydrocephalus 
were excluded. The trend did not change compared with the 
main analysis.
nPs assessment
The outcome of the NPS assessment was available for 71 patients. 
Only one patient had a normal test performance; 44 patients were 
diagnosed as affected by diffuse cognitive impairment; and 26 
patients were diagnosed as affected by MCI. Age was no signifi-
cantly different between patients with diffuse cognitive impair-
ment (mean 76.4 years, SD ±3.8) and patients with MCI (mean 
76.4 years SD ±5.5). Twenty-six of the 27 patients classified as 
with no dementia according to the NIA-AA criteria (96.3%) were 
diagnosed as affected by MCI, most of them (88%) with deficits 
in multiple cognitive domains. In particular, the definition into 
MCI subtypes was available for 25 patients: three (12%) patients 
were classified as single MCI with only memory domain affected; 
15 (60%) patients were classified as multiple domain MCI with 
memory domain affected; and seven (26%) patients were classi-
fied as multiple domain MCI with deficits other than on memory 
domain. No patient was classified as single-domain MCI with a 
deficit other than on memory domain.
Tables 7 and 8 show the frequency of liquor positivity accord-
ing to the NPS outcome and MCI phenotypes, respectively. 
There was no statistically significant difference in the frequency 
of positivity across NPS definitions. In particular, the biomarker 
liquor tended to be more frequently positive in patients with 
MCI than in patient with diffuse cognitive impairment.
cerebrovascular Burden  
at neuroimaging
MRI images were available for 40 patients. Thirty-two of these 
40 (80%) patients had a diagnosis of cerebrovascular damage 
according to the qualitative report made by the radiologist. 
Mean Fazekas score was 1.55 ±  1. According to the Fazekas 
score 18 of the 40 (45%) patients were positive. Table 9 shows 
the mean Fazekas scores and positivity according to the clinical 
diagnostic criteria. According to both clinical classifications, 
Fazekas was positive in about half of the patients with no 
dementia or possible AD, while it was positive in about one-
third of the patients with probable AD. When only patients 
with a diagnosis of probable AD according to the NIA-AA 
criteria were considered, the proportion of patients with a 
positive Fazekas in progressively younger subgroups remained 
the same or increased compared with the whole population 
or with the oldest ones (Table 10). The results were the same 
for patients with probable AD according to DSM-IV plus 
NINCDS-ADRDA criteria.
FigUre 1 | Distributions of amyloid-β (Aβ), total Tau (Tau), and phosphorylated Tau (p-Tau) values in no dementia, possible Alzheimer’s disease (AD) and probable 
AD patients according to Diagnostic Statistical Manual of Mental Disorders (DSM-IV) plus National Institute of Neurological and Communicative Disorders and Stroke 
and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) and National Institute on Aging-Alzheimer’s Association (NIA-AA) criteria. Legend: 
mean (SD) concentration is provided for each diagnostic category. *Kruskal–Wallis test for difference in the protein distribution across diagnostic groups.
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When in the same patients with a clinical diagnosis of prob-
able AD (according to NIA-AA or NINCDS-ADRDA criteria) 
the Fazekas results were cross-tabulated with the CSF results 
(Table  11), there was no statistically significant difference in 
frequency distribution.
DiscUssiOn
Our retrospective analysis of a cohort of patients with a cogni-
tive deficit referring to a geriatric outpatient clinic (mean age 
78 years), confirmed a non-negligible discrepancy between the 
TaBle 7 | Positivity of the biomarker according to different neuropsychological 
(NPS) diagnosis.
Positive liquor among 
all patients with nPs 
assessment (71), n (%)
Positive liquor among 
those patients with nPs 
assessment with no 
normotensive hydrocephalus 
suspect (62), n (%)
Cognitive normal 1 (100) –
Mild cognitive 
impairment
7 (27) 7 (35)
Diffuse cognitive 
impairment
10 (23) 10 (24)
Total 18 (25) 17 (27)
TaBle 6 | Distribution of the biomarker liquor according to National Institute on 
Aging-Alzheimer’s Association (NIA-AA) diagnosis in patients without a clinical 
suspicion of normotensive hydrocephalus.
Diagnosis nia-aa criteria Positive liquor, n (%) Pearson χ2, p
No dementia 7 (35) 0.102
Possible AD 1 (4)
Probable AD 9 (32)
Any 17 (27)
TaBle 5 | Distribution of the biomarker liquor according to the Diagnostic Statistical Manual of Mental Disorders (DSM-IV) plus National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADDRDA) and National Institute on Aging-Alzheimer’s 
Association (NIA-AA) diagnosis and age groups.
age (years) DSM-iV plus nincDs-aDrDa criteria nia-aa criteria
Diagnosis Positive liquor, n (%) Pearson χ2, p Diagnosis Positive liquor, n (%) Pearson χ2, p
Any No dementia 8 (15) 0.208 No dementia 8 (21) 0.027
Possible AD 2 (15) Possible AD 2 (4)
Probable AD 8 (31) Probable AD 8 (32)
≥80 No dementia 2 (7) 0.324 No dementia 2 (11) 0.321
Possible AD 0 (0) Possible AD 0 (0)
Probable AD 1 (20) Probable AD 1 (20)
<80 No dementia 6 (24) 0.494 No dementia 6 (27) 0.168
Possible AD 2 (16) Possible AD 1 (7)
Probable AD 7 (33) Probable AD 8 (35)
TaBle 4 | Relationship between CSF biomarkers and clinical diagnosis.
Diagnostic Statistical Manual of Mental Disorders-iV plus national 
institute of neurological and communicative Disorders and stroke and 
the alzheimer’s Disease and related Disorders association criteria
national institute on aging- alzheimer’s association 
criteria
amyloid-β (aβ) Total tau (Tau) Phosphorylated tau (p-Tau) aβ Tau p-Tau
Positive, n (%) Positive, n (%) Positive, n (%) Positive, n (%) Positive, n (%) Positive, n (%)
No dementia 20 (36) 17 (31) 19 (35) 16 (41) 12 (31) 15 (39)
Possible AD 5 (38) 5 (38) 7 (54) 8 (30) 8 (30) 9 (33)
Probable AD 18 (69) 13 (50) 13 (50) 19 (68) 15 (54) 15 (54)
Pearson χ2, p 0.012 0.251 0.261 0.013 0.102 0.277
TaBle 8 | Positivity of the biomarker liquor according to different mild cognitive 
impairment (MCI) phenotypes and age groups.
age 
(years)
neuropsychological 
phenotype
negative liquor, 
n (%)
Positive liquor, 
n (%)
≥80 Amnestic MCI 0 0
Multiple domain MCI+ 3 (60) 2 (40)
Multiple domain MCI− 5 (100) 0 (0)
<80 Amnestic MCI 2 (67) 1 (33)
Multiple domain MCI+ 7 (70) 3 (30)
Multiple domain MCI− 1 (50) 1 (50)
+, with amnestic component; −, without amnestic component.
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diagnosis of AD when based on clinical criteria, CSF biomarkers, 
or neuroimaging.
First, we confirmed a substantial discordance between 
the two sets of clinical diagnostic criteria, i.e., DSM-IV plus 
NINCDS-ADRDA (1984) versus NIA-AA (2011) criteria, with 
an agreement of only 70% when adjusted for the effect of chance. 
The discordance likely reflects the evolution in the definition 
of dementia and AD and was someway expected. However, we 
wanted to quantify this discrepancy in a cohort of patients with 
a higher probability of a complex phenotype, since 1984 criteria 
have been used to define patient eligibility for approval studies 
of many current drugs available for AD and are still being used 
in research (13, 26–29). According to our data, most (16 out of 
27, 59%) of the “possible AD” patients according to the newer 
criteria would have been classified as “no dementia” by the older 
approach (Table 3) and would have been not eligible for those 
studies. The results of those studies are therefore not necessar-
ily applicable to this subset of patients defined as “possible AD” 
according to a more comprehensive understanding of the disease.
TaBle 11 | Correlation of the biomarker liquor and cerebrovascular burden at 
neuroimaging according to Fazekas scores, in subjects with a clinical diagnosis 
of probable AD (National Institute on Aging-Alzheimer’s Association criteria) in 
different age subgroups.
negative Fazekas, n (%) Positive Fazekas, n (%) p
Total
Negative liquor 6 (67) 3 (33) 0.764
Positive liquor 3 (75) 1 (25)
<80 years
Negative liquor 4 (67) 2 (37) 0.778
Positive liquor 3 (75) 1 (25)
≥80 years
Negative liquor 2 (67) 1 (33) –
Positive liquor 0 (0) 0 (0)
≤75 years
Negative liquor 1 (50) 1 (50) 0.709
Positive liquor 2 (67) 1 (33)
>75 years
Negative liquor 5 (71) 2 (29) 0.537
Positive liquor 1 (100) 0 (0)
TaBle 10 | Distribution of the positive Fazekas score in different age subgroups 
in people with a clinical diagnosis of probable AD (National Institute on Aging-
Alzheimer’s Association criteria).
age (years) Positive Fazekas, n (%)
≥80 1 (33)
<80 3 (30)
<75 2 (40)
<72 1 (100)
TaBle 9 | Cerebrovascular damage at neuroimaging according to the Fazekas scale and clinical diagnosis of dementia.
Diagnosis Diagnostic Statistical Manual of Mental Disorders-iV plus 
national institute of neurological and communicative Disorders 
and stroke and the alzheimer’s Disease and related Disorders 
association criteria
national institute on aging-alzheimer’s association criteria
Fazekas, mean (sD) Positive Fazekas,a 
n (%)
p (Pearson χ2 test) Fazekas, mean (sD) Positive Fazekas,a 
n (%)
p (Pearson χ2 test)
No dementia 1.1 (1.1) 12 (52) 0.453 1.6 (1.1) 10 (53) 0.451
Possible AD 1.2 (0.9) 2 (50) 1.6 (1.1) 4 (50)
Probable AD 1.4 (1.0) 4 (31) 1.3 (1.0) 4 (31)
aScore ≥2.
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One of the main differences between the two criteria is 
that the older ones, but not the newer, include the presence 
of amnesic deficits as a necessary criterion for AD diagnosis. 
Interestingly, in our cohort, the majority of patients (64%), 
who had no objective memory deficiency at the NPS tests, 
had in fact complained about forgetfulness during the clinical 
visit. This datum has been already described in the literature 
(30). This confirmed the role of the NPS assessment, which 
in practice might be sometimes forgone in the assessment of 
the oldest old patients. An extended NPS battery helped us 
to better define not only the phenotype but also the severity 
of the cognitive disorder (6, 31, 32), which, in some cases, 
allowed us to suppose a higher functional impairment, or a 
higher contribution of the cognitive deficits to the functional 
impairment, among other possible health and social contribu-
tors, compared to what the interview with the patients or their 
caregivers had suggested.
The distribution of the CSF biomarkers levels in our popula-
tion was quite sparse, even in patients with a clinically probable 
AD. In particular, patients with positive liquor biomarkers still 
represented a minority among those that would have been 
classified as probable AD based on clinical criteria only; they 
represented the majority only in a younger (i.e., <76  years) 
subset of patients. In 2012, Mattsson et  al. investigated the 
effect of age on the diagnostic performance of CSF biomarkers 
in a large multi-center study population and they found that 
although the diagnostic accuracy for AD decreased with age, 
the predictive values for a combination of biomarkers remained 
essentially stable. In comparison with our population, their 
cross-sectional cohort of patients with AD had a lower median 
age (71 versus 77.7), an higher percentage of male subjects 
(57 versus 38.3%) and a lower MMSE median score (22 versus 23.9) 
(33). In that study the clinical diagnosis of AD was based on 
DSM-IV plus NINCDS-ADRDA criteria. In our study too, 
there was a non-statistically significant trend for an increased 
liquor positivity going from “no dementia” to “possible” and 
then “probable AD,” only when the DSM-IV plus NINCDS-
ADRDA were used. This suggests a higher concordance between 
the CSF biomarkers so far known and the classical AD vari-
ant, rather than with the more comprehensive AD definition. 
In contrast, when we looked at the relationship between the 
CSF protein distribution and the NPS outcome, we did not 
find the expected association between a classical amnesic MCI 
phenotype and positive biomarkers.
Our findings confirm that quantitative methods based on 
neuroimaging (i.e., the Fazekas scale) can help refine the clas-
sification of patients upon the degree of cerebrovascular dam-
age compared to descriptive radiological reports (34). Yet, the 
clinical relevance of neuroimaging remains uncertain among 
relatively older patients. Indeed, we less frequently found a 
positive Fazekas in patients with probable AD, compared with 
patient with possible or no AD, suggesting that the vascular 
damage is not a typical pathogenic mechanism of the disease. 
However, there was still a substantial percentage (31%) of posi-
tive Fazekas among patients with probable AD. Furthermore, 
we found that a positive Fazekas tended to be only slightly 
more frequent among probable AD with negative liquor than 
among those with a positive liquor, regardless of age. This finally 
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